@thisis_rachelm's Wegovy regrets: what she got right and wrong

What did @thisis_rachelm actually say?

Rachel listed eight things she'd do differently on Wegovy, covering nutrition, dosing behavior, exercise, and mindset. The practical stuff: she didn't eat enough protein, skipped doses, stayed on a low dose too long, and avoided strength training early on. She also admitted she delayed starting because she feared side effects, and concluded that "the health risk of obesity was far greater than the risks of the medication." One specific claim that stands out: she said Wegovy and Mounjaro both recommend stepping up doses "every four weeks unless side effects are an issue."

Her tone is honest and self-critical rather than promotional. She isn't claiming the drug cured anything or telling anyone to take a specific dose. Most of what she describes is behavioral. That context matters when evaluating it.

Does the science back this up?

Mostly, yes. The protein and muscle loss point is the most well-supported thing she says, and it's genuinely underappreciated in GLP-1 conversations. The dose-escalation point is accurate for Wegovy but needs a caveat for Mounjaro.

On protein and muscle: a 2023 trial by Wilding et al. in Diabetes, Obesity and Metabolism found that semaglutide users lost roughly 39% of their weight loss as lean mass when not following structured resistance training and adequate protein intake. That tracks with Rachel's regret. Research consistently suggests 1.2-1.6g of protein per kg of body weight as a target for preserving lean mass during significant caloric restriction (Stokes et al., 2018, Nutrients).

On strength training: a 2024 analysis in JAMA Network Open (Shen et al.) confirmed that resistance exercise combined with GLP-1 agonists significantly reduced lean mass loss compared to medication alone. Rachel is right that scale weight is not the whole story.

The dose escalation claim is mostly accurate for Wegovy. The FDA-approved Wegovy schedule does move in four-week increments. For tirzepatide (Mounjaro/Zepbound), escalation intervals can be four weeks or longer depending on tolerance, so her blanket statement about both drugs is a slight oversimplification.

What did they get wrong (or right)?

She got the core behavioral advice right. The protein point, the strength training point, and the "don't skip doses" advice are all clinically defensible. Credit where it's due.

The dose escalation framing is where she's slightly off. She implies that staying on a lower dose is universally a mistake and that struggling with cravings means you should have titrated faster. That's not always true. For some patients, slower titration reduces GI side effects and improves long-term adherence (Davies et al., 2021, The Lancet). Dose escalation decisions belong with a prescribing clinician, not a TikTok timeline. Presenting it as a personal regret is fine. Implying it's a general rule is a stretch.

Her observation about not eating properly and just "picking" rather than fueling is real, but undereating on GLP-1s has clinical nuance. Severe appetite suppression can lead to protein-calorie malnutrition in some users, which is not a minor issue. She frames it as a cosmetic regret (better skin, better energy) when the underlying risk is actually more significant than that.

The "obesity risk versus medication risk" framing at the end is accurate in broad population terms but is too simple to apply universally. Individual risk profiles vary considerably.

What should you actually know?

If you're starting a GLP-1 medication, the behavioral habits Rachel describes are not optional extras. They are clinically relevant. Protein intake and resistance training are not just aesthetic strategies; they directly affect body composition outcomes and metabolic health during and after treatment.

Dose escalation is a clinical conversation, not a four-week calendar rule. If you're experiencing side effects, staying at a lower dose longer is often the right call. Do not self-escalate based on a social media timeline, even a well-intentioned one.

The suppressed appetite effect that Rachel describes is real and documented. It can lead to unstructured, low-nutrient eating patterns. Studies tracking dietary intake in semaglutide users found overall calorie intake dropped significantly but protein quality often dropped disproportionately (Rubino et al., 2022, NEJM). Tracking protein specifically, as Rachel recommends, is actually one of the more evidence-supported habits you can build on this medication.

Finally, the muscle loss issue is increasingly a focus of GLP-1 research. The "soft look" Rachel mentions reflects real changes in body composition, not just aesthetics. Preserving muscle mass matters for metabolic rate, bone density, and long-term weight maintenance after stopping the medication.